Sarcomas/TGCT Articles

Pathological Fractures Linked to Inferior OS in Adults With Osteosarcoma
Pathological fractures in adult patients with high-grade osteosarcoma of the extremities potentially correlates with inferior overall survival.
Orthopedic Oncologists Essential to Optimal QoL for Patients With Metastatic Bone Disease
R. Lor Randall, MD, discusses the referral challenges for orthopedic oncologists and the importance of improving quality of life for patients with metastatic bone disease.
Novel Surgical Technique Alleviates Adverse Events After Amputation in Patients With Cancer
Thomas J. Scharschmidt, MD, MBOE, discusses the use of targeted muscle reinnervation for amputee patients with cancer as well as therapeutic advances in sarcoma and tenosynovial giant cell tumor.
P16, P21 Biomarkers Linked to Treatment Response in Osteosarcoma
C. Parker Gibbs, MD, discusses the research behind p16 and p21 as predictive biomarkers for treatment response in patients with osteosarcoma.
FDA Approves Tazemetostat for Epithelioid Sarcoma
The FDA has granted an accelerated approval to tazemetostat for the treatment of adult and pediatric patients aged ≥16 years old with metastatic or locally advanced epithelioid sarcoma that is not eligible for complete resection.
FDA Grants ADP-A2M4 RMAT Designation for Synovial Sarcoma
The FDA has granted a Regenerative Medicine Advanced Therapy designation to ADP-A2M4 (MAGE-A4) as a treatment for patients with synovial sarcoma.
FDA Grants SP-2577 Fast Track Status for Ewing Sarcoma
The FDA has granted fast track designation to the potent reversible LSD1 inhibitor SP-2577 (seclidemstat) for the treatment of relapsed/refractory patients with Ewing sarcoma.
ADP-A2M4 Shows Early Promising Clinical Activity in Synovial Sarcoma
Brian A. Van Tine, MD, PhD, discusses the results of a phase I study looking at the effects of ADP-A2M4 in patients with synovial sarcoma.
FDA Panel Supports Tazemetostat for Epithelioid Sarcoma
The FDA’s Oncologic Drugs Advisory Committee voted in favor of approving tazemetostat tablets as a treatment for patients with metastatic or locally advanced epithelioid sarcoma that is ineligible for curative surgery.
 
FDA Schedules ODAC Meeting on Tazemetostat for Epithelioid Sarcoma
The FDA has scheduled an Oncology Drugs Advisory Committee hearing for December 18, 2019, to discuss data supporting a new drug application for tazemetostat as a treatment for patients with metastatic or locally advanced epithelioid sarcoma that is ineligible for curative surgery.
Publication Bottom Border
Border Publication
x